As reported recently in a clinical study, NBP combination with Edaravone treatment significantly decreased serum Tumor necrosis factor-α (TNF- α), C-reactive protein (CRP), and Interleukin-6 (IL-6) levels of ischemic stroke patients (Li et al. 2023). The gene discussed is CRP; the disease is ischemic stroke.